MA
ABBV icon

Modus Advisors’s AbbVie ABBV Stock Holding History

Modus Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.58M Buy
25,641
+594
+2% +$132K 1.54% 21
2025
Q4 		$5.72M Sell
25,047
-360
-1% -$82K 1.51% 22
2025
Q3 		$5.88M Buy
25,407
+649
+3% +$132K 1.6% 22
2025
Q2 		$4.6M Buy
24,758
+107
+0.4% +$19.9K 1.37% 27
2025
Q1 		$5.16M Buy
24,651
+115
+0.5% +$22.4K 1.69% 22
2024
Q4 		$4.36M Buy
24,536
+428
+2% +$78.7K 1.37% 28
2024
Q3 		$4.76M Buy
24,108
+289
+1% +$53.9K 1.56% 24
2024
Q2 		$4.09M Buy
23,819
+660
+3% +$109K 1.45% 24
2024
Q1 		$4.22M Buy
23,159
+450
+2% +$77.6K 1.56% 23
2023
Q4 		$3.52M Buy
22,709
+494
+2% +$72K 1.43% 25
2023
Q3 		$3.31M Buy
22,215
+341
+2% +$50.1K 1.44% 25
2023
Q2 		$2.95M Buy
21,874
+1,092
+5% +$160K 1.27% 28
2023
Q1 		$3.31M Buy
20,782
+82
+0.4% +$12.5K 1.53% 21
2022
Q4 		$3.35M Buy
20,700
+224
+1% +$34.3K 1.62% 19
2022
Q3 		$2.75M Buy
20,476
+30
+0.1% +$4.3K 1.45% 26
2022
Q2 		$3.13M Buy
20,446
+539
+3% +$82.4K 1.59% 23
2022
Q1 		$3.23M Buy
19,907
+69
+0.3% +$10K 1.42% 25
2021
Q4 		$2.69M Sell
19,838
-622
-3% -$73.5K 1.14% 32
2021
Q3 		$2.21M Buy
20,460
+799
+4% +$91.3K 0.96% 33
2021
Q2 		$2.21M Sell
19,661
-487
-2% -$54.8K 0.93% 33
2021
Q1 		$2.18M Buy
20,148
+1,825
+10% +$195K 1.01% 33
2020
Q4 		$1.96M Buy
18,323
+1,152
+7% +$111K 1.02% 32
2020
Q3 		$1.5M Buy
17,171
+4,389
+34% +$413K 0.86% 37
2020
Q2 		$1.25M Buy
12,782
+4,083
+47% +$359K 0.82% 35
2020
Q1 		$663K Buy
+8,699
New +$741K 0.61% 28

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Modus Advisors's ABBV Position: Q1 2026 in Review

Modus Advisors increased its AbbVie (ABBV) stake by 2.4% in Q1 2026, buying an estimated $132K and bringing the position to 25,641 shares worth $5.58M. The position accounts for 1.54% of the portfolio, ranked #21.

Modus Advisors first reported a position in ABBV in Q1 2020 and has held it in 25 quarters since. The position peaked at $5.88M in Q3 2025. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Modus Advisors held 25,641 shares of AbbVie worth $5.58M as of Q1 2026.
  • Modus Advisors bought 594 AbbVie shares in Q1 2026, an estimated $132K.
  • AbbVie made up 1.54% of Modus Advisors's portfolio in Q1 2026, its #21 holding.
  • Modus Advisors first reported a position in AbbVie in Q1 2020 and has held it in 25 quarters since.
  • Modus Advisors's AbbVie position peaked at $5.88M in Q3 2025.
  • 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Modus Advisors's 13F filing for Q1 2026, filed 4 May 2026.